FTC Takes Sweeping Action Against Big Pharma’s Sham Patent Game, Ensuring Inhalers, EpiPens, and More Are Affordable and Accessible
November 7, 2023 — The Federal Trade Commission (FTC) announced new action today to challenge 100+ patents of brand name inhalers, epinephrine auto injectors and more — which follows the Commission’s passage of a policy statement condemning improper listing of patents in the Food and Drug Administration’s (FDA) Orange Book. In response, the American Economic Liberties Project released the following statement:
November 1, 2023 — As the House considers the Fiscal Year 2024 Transportation, Housing and Urban Development, and Related Agencies bill—an appropriations bill carrying a dangerous amendment, supported by House antitrust subcommittee chair Thomas Massie (R-KY) and ranking member Lou Correa (D-CA), to neuter the competition authorities of the Department of Transportation and other enforcers—the American Economic Liberties Project released the following statement:
Amazon’s Own Executives Admit That Amazon Hurts Consumers and Inflates Prices, Updated FTC Complaint Reveals
November 2, 2023 — In response to a newly released version of the Federal Trade Commission’s complaint against Amazon, which makes public substantial previously-redacted information, the American Economic Liberties Project released the following statement.
November 1, 2023 — Ahead of Apple’s earnings call this week, the American Economic Liberties Project urges investors and analysts to ask Apple about its contract with Google, where, according to the U.S. v. Google trial, Google has paid Apple billions of dollars for 18 years to remain the default search.
November 1, 2023 — In response to news that the Attorney General of D.C., Brian Schwalb, has filed an antitrust suit against RealPage and 14 residential landlords for colluding to raise prices by sharing competitive data, the American Economic Liberties Project released the following statement.